Fen Phen Lawsuit Loans

Have a Settled Fen Phen Lawsuit But Need Cash Now?

TriMark Legal Funding provides post-settlement funding on settled Fen-Phen lawsuits nationwide.

Legal Funding on Fen-Phen Lawsuits

TriMark Legal Funding is one of America’s leading personal injury accident loan companies. We provide pre-settlement funding and post-settlement funding (lawsuit loans) to injured plaintiffs nationwide while they wait for their lawsuit settlements.

At TriMark Legal Funding, we offer non-recourse lawsuit funding cash advances to plaintiffs who are involved in either pending or settled legal claims, often in 24 hours or less.

Lawsuit loans are a discreet, sensible way to keep your head above water until your attorney has finished negotiating your lawsuit settlement.

Let’s Talk!

Call us at (877) 932-2628 or send us your details & we’ll call you.

    Have Questions?
    Call and speak with one of our funding experts today.

    Important Notice About Fen-Phen Lawsuit Funding

    TriMark Legal Funding only offers post-settlement funding on settled Fen Phen lawsuits at this time

    This means that to qualify for funding consideration, you must have already signed your settlement agreement and know either

    1. The gross amount of your settlement OR
    2. The actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, etc.)

    If you have a settled Fen Phen lawsuit and would like to apply for settlement funding, please apply here.

    How Lawsuit Loans Work

    TriMark Legal Funding specializes in helping personal injury accident victims.
    Our non-recourse legal funding is a simple 3-step process:

    1. Apply for Funding

    You can either apply online or call us toll-free at (877) 932-2628. We’ll answer all of your questions and gather some basic facts about your case.

    2. Review & Approval

    Our team will work directly with your attorney to review your case. Approvals can happen as quickly as 1 hour after receipt of all required information.

    3. Receive Cash

    A funding agreement is sent via DocuSign. After signed copies are returned, your cash is sent to you by wire transfer or FedEx Overnight.

    Fen-Phen Lawsuit Funding

    TriMark Legal Funding LLC provides fast, affordable lawsuit post-settlement funding cash advances from $1,000 up to $25,000 – often in as little as 48 hours for plaintiffs with settled Fen Phen lawsuits. We also offer lawsuit loans for defective drug lawsuits, defective medical devices, and many other types of multidistrict litigation and personal injury cases.

    Fen Phen Side Effects: Primary Pulmonary Hypertension

    Fen-Phen, a diet drug marketed as Redux, Fenfluramine, Dexfenfluramine, and Pondimin, had been considered safe for many years until the FDA requested its removal from store shelves in 1997. Rising reports of heart valve disease caused the FDA to take the action against Fen-Phen, particularly after echocardiograms of women who had ingested the drug indicated a 30% rate of heart valve abnormality, even though no other symptoms had been reported.

    atients suffering from Primary Pulmonary Hypertension (PPH) caused by Fen-Phen are NOT involved in the Nationwide Class Action Settlement Agreement with American Home Products. PPH patients must file independent lawsuits to make legal claims. TriMark Legal Funding LLC funds on both the Fen-Phen class action suit and independent PPH lawsuits.

    What is Fen-Phen?

    Fen-Phen (also marketed under the names Phen-Fen, Pondimin and Redux) is an anti-obesity medication consisting of two drugs: fenfluramine and phentermine. Fenfluramine, and later, a related drug, dexfenfluramine, was marketed by Wyeth, now known as American Home Products.

    Fen-Phen Maker Agrees to $3.75 Billion Settlement

    American Home Products Corporation (AHP), makers of the diet drug combination Fen-Phen, agreed Thursday to pay $3.75 billion in compensation to thousands of people who used the diet drugs and developed Primary Pulmonary Hypertension (PPH) before they were removed from the market in 1997 after being linked to heart valve disease.

    After reports of valvular heart disease and pulmonary hypertension, primarily in women who had been undergoing treatment with Fen-Phen, the Food and Drug Administration (FDA) requested its withdrawal from the market in September 1997.

    Fen-Phen decreased hunger by increasing Seratonin levels in the brain, which then caused the user to have feelings of fullness or satiety. Fenfluramine (Fen) the first ingredient in the drug, when used alone was shown to cause severe mood swings and depression. So, phentermine (Phen) was added to Fen, because it effectively counterbalanced depression, and the two drugs working as one were able to stave off hunger, without any of the resultant emotional problems.

    But, it was found that the combination of these two ingredients in Fen-Phen was not safe, and severe health consequences resulted from patient usage, despite Fen Phen lawyers arguing there was no connection.

    As a result of these findings, Fen-Phen class-action lawsuits have grown to over 500,000 since April 2005, according to American Lawyer magazine, and Fen-Phen lawyers should only anticipate more filings to come.

    Cases of Fen-Phen and SSRI-Related Lung Disorder Rise


    • Abilify
    • Accutane
    • Actonel
    • Actos
    • Androgel
    • Avandia
    • Avelox
    • Baycol
    • Belviq
    • Bextra
    • Boniva
    • Celebrex
    • Cipro
    • Coumadin
    • Crestor
    • Darvocet
    • Darvon
    • Dexatrim
    • Dexilant
    • Eliquis
    • Ephedrine
    • Fen-Phen
    • Fluoroquinolones
    • Fosamax
    • Gadolinium Dye
    • GranuFlo & NaturaLyte
    • Heparin
    • Invokana
    • Levaquin
    • Lipitor
    • Lipobay
    • Losartan
    • Meridia
    • Nexium
    • Paxil
    • Pergolide
    • Permax
    • Plavix
    • Prempro
    • Prevacid
    • Prexige
    • Prilosec
    • Propulsid
    • Proton Pump Inhibitors (PPI)
    • Protonix
    • Prozac
    • Raptiva
    • Ranitidine
    • Reglan
    • Rezulin
    • RotaShield
    • Seldane
    • Seroquel
    • Taxotere
    • Testosterone
    • Topomax
    • Trasylol
    • Trovan
    • Truvada
    • Valsartan
    • Vioxx
    • Warfarin
    • Yasmin
    • Yaz
    • Zantac
    • Zelnorm
    • Zocor
    • Zofran
    • Zoloft
    • Zyban
    • Zyprexa

    Medical Devices

    • Bair Hugger
    • ERCP Scope
    • Guidant Heart Device
    • IUD Litigation
      • Mirena IUD
      • Paragard IUD
    • Kugel Mesh Patch
    • Medtronic
      • Infuse Bone Graft
      • Marquis Defibrillator
      • Sprint Fidelis
    • NuvaRing
    • Ortho Evra Patch
    • Phillips CPAP
    • Power Morcellator
    • Surgical Robot
      • Da Vinci Robot

    Products / Other

    • 9/11 First Responder Settlements
    • Big Tobacco
    • Class Action Lawsuits
    • Commercial Litigation Funding
    • Deepwater Horizon MDL 2179
    • Dow Corning Breast Implant
    • DuPont C-8 (Teflon) MDL 2433
    • E-Cigarettes
      • JUUL
    • FIU Bridge Collapse
    • Hertz False Arrest Lawsuit
    • Iraq War Hostages
    • Paraquat Weedkiller
    • PG&E Wildfire Lawsuits
    • Sports Injury Lawsuits
      • NCAA Concussion
      • NFL Concussion
      • WWE Concussion
    • Takata Airbag Settlement

    Apply For Fen-Phen Lawsuit Settled Case Funding

    Lawsuit Funding FAQ Apply Now

    To qualify for an Accutane lawsuit cash advance, you must have a settled Fen Phen lawsuit. Pending lawsuits are not eligible at this time.

    To qualify, you must have an already signed Fen Phen settlement agreement which clearly shows either the gross amount of your settlement or the actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, medical hold-backs, etc.) have been made.

    If you have a settled Fen-Phen lawsuit and need funding, either:

    Call Us At (877) 932-2628 or

    Latest Developments in the Fen-Phen Lawsuit…

    Fen Phen lawyer Cynthia K. Garrett reports that worsened injury claims may still be filed for those who took the diet drugs Pondimin or Redux, registered with the AHP Settlement Trust by May 3, 2003, established the required baseline injury during the Screening Period that ended in 2003, did not participate in the Seventh Amendment Supplemental Fund, and currently qualify for a Matrix Compensation Level and dollar value above any previous award received. Garrett explained, "Whether you can still file a claim depends upon the nature and extent of your injury, when your worst injury was first diagnosed, and what has previously been filed in your case. The criteria you must meet to file a claim today is discussed at length on my website, CKGLawFim.com. I've provided you with a quick summary below." Who Can Still File A Claim: Qualifying injuries must have been diagnosed prior to your 80th birthday…. Read more
    Pfizer just can't get rid of the specter of fen-phen. Fifteen years after the diet drug was removed from the market over serious health concerns, litigation lingers and the drugmaker's move to kill that off fell short yesterday. Pfizer has reserved $21 billion for fen-phen litigation over the years but hoped to have remaining suits dismissed. But a judge in Philadelphia, where most of the suits are consolidated, wasn't buying it. He said plaintiffs can use studies from experts that indicate that fen-phen can instigate primary pulmonary hypertension, even more than a decade after consumers stopped taking the appetite suppressant. Pfizer tells Bloomberg that it is weighing its legal options. Pfizer bought the problem when it acquired the drug's developer Wyeth in 2009, 12 years after fen-phen was banned in the U.S. More than 6 million prescriptions had been written when it was on the market, Bloomberg says, and at one time there… Read more
    Study Shows Lingering Heart Valve Problems in Former Users of Banned Obesity Drugs Fenfluramine and Dexfenfluramine Two banned obesity drugs may have lingering effects on the heart, according to a new study. The study shows that heart valve problems linked to the banned obesity drugs fenfluramine and/or dexfenfluramine typically last years after stopping those drugs. The FDA ordered fenfluramine and dexfenfluramine off the market in September 1997 after those drugs were linked to heart valve problems. Fenfluramine was one of the ingredients in "fen-phen," and dexfenfluramine is closely related to fenfluramine. The "phen" in fen-phen refers to a drug called phentermine, which wasn't banned. The new study, published online today in BMC Medicine, shows what happened to the hearts of 5,743 former users of fenfluramine and/or dexfenfluramine. Heart Valve Problems The patients were seen by doctors including Charles Dahl, MD, of the Central Utah Clinic in Provo, Utah, between July 1997 and February 2004. During that… Read more
    Two of the owners of the Preakness champion Curlin were indicted yesterday by a federal grand jury on a charge that they conspired to defraud their clients in a $200 million lawsuit settlement with the maker of the diet drug fen-phen. The grand jury in Covington, Ky., indicted the lawyers Shirley A. Cunningham Jr., 52, and William J. Gallion, 56, on one count each of conspiracy to commit wire fraud. If convicted, each could receive a maximum of 20 years in prison and a $250,000 fine. The federal sentencing guidelines are no longer mandatory, so it is unlikely they will receive the maximum penalty if they are found guilty. The grand jury also handed up one forfeiture count each, which would require the defendants, if … Read more
    In the fall of 1997, American Home Products Corporation, which became Wyeth in 2002, withdrew the drugs Pondimin (fenfluramine), and Redux (dexfenfluramine), which were prescribed together with phentermine for weight loss, in a combination called "fen-phen," for short. Fen-phen causes the life-threatening lung disorder known as primary pulmonary hypertension, or PPH. According to the Pulmonary Hypertension Association, PPH is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery rises above normal levels and can become life threatening. As the blood is pumped through the arteries in the lungs, it receives oxygen; this oxygenated blood returns to the heart where it is then transported to the rest of the body through the aorta and other arteries. Changes to the … Read more
    Three attorneys have been temporarily suspended from practicing law in Kentucky because of questions about the way they divided a $200 million settlement from a fen-phen lawsuit. The Kentucky Supreme Court took the action in written rulings released last Thursday. In an order signed by Deputy Chief Justice Will T. Scott, justices said they found probable cause to believe that the attorneys had diverted funds to their own use. Linda Gosnell, chief counsel for the Kentucky Bar Association, had argued before the Supreme Court last week that the attorneys — William Gallion, Shirley Cunningham Jr. and Melbourne Mills — improperly took more than their share of the settlement. The lawyers, all from Lexington, represented hundreds of clients in a lawsuit over the diet drug. “Their conduct was drastic,” Gosnell told the court. “This is a case of absolute, unbridled greed.” The Kentucky Bar Association’s Inquiry Commission had recommended the temporary… Read more

    See More